KRT-232

KRT-232 is a small-molecule drug developed by Kartos Therapeutics. Its targets are MDM2 and TP53 (the sponsor names MDM2-p53 interaction). The sponsor states: A novel, potent and selective oral MDM2 inhibitor, referred to on the current site as navtemadlin. ClinicalTrials.gov describes the intervention as: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in myeloproliferative neoplasms, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT04502394, plans to enrol 84 participants with primary completion expected 2022-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.